Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18362236 | 0.87 | PDE2A (0.63) | PDE2A | |
| SCHEMBL20175957 | 0.82 | PDE2A (0.50) | PDE2A | |
| SCHEMBL20175953 | 0.79 | ALDH1A1 (0.37) | PDE2AADORA3CYP2C9CYP2C19 | |
| SCHEMBL20175962 | 0.75 | PDE2A (0.37) | PDE2AADORA3KDM4ECYP2C9CYP2C19 | |
| SCHEMBL20175952 | 0.74 | PDE2A (0.76) | PDE2AADORA3KDM4ECYP1A2PARP1 | |
| SCHEMBL20175960 | 0.71 | PDE2A (0.77) | PDE2A | |
| SCHEMBL18362216 | 0.71 | PDE2A (0.51) | PDE2AKDM4E | |
| SCHEMBL11803855 | 0.70 | — | — | |
| SCHEMBL20164033 | 0.69 | PDE2A (0.49) | PDE2A | |
| SCHEMBL18362237 | 0.68 | PDE2A (0.46) | PDE2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141952-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | PDE2A 1/4885ADORA3 1453/4885KDM4E 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.